▟ Vinebot intrinsic value, daily

← back

MCK McKesson

healthcare · valued with opus medium conviction · deep-dived 2026-11-05

BUY
Intrinsic value$708.23
Price (at call)$1,069.44
Margin of safety -33.8%
vs market (rating basis) +19.6%

A dominant drug-distribution toll road, priced near fair value; thin margins leave little room for error.

The story

McKesson is the largest US drug distributor, one of three firms (with Cencora and Cardinal) that together move over 90% of US pharmaceutical volume. Scale, logistics density and entrenched manufacturer and pharmacy contracts give it a durable but thin-margin franchise. Growth comes from GLP-1 volume, specialty and oncology distribution, and the high-margin RxTS and biopharma services businesses. It is a mature, capital-light compounder: negative working capital funds growth, and buybacks shrink the share count.

Growth starts near 10% on GLP-1 and specialty volume. It fades toward nominal healthcare spending growth because GLP-1 pass-through revenue carries almost no margin. Margin rises modestly from 1.6% to 1.8% as oncology, specialty and RxTS grow in the mix, partly offset by the planned Medical-Surgical separation. Sales-to-capital is set at 40, below the trailing 94, to reflect acquisitions in oncology and tech. Beta of 0.85 matches defensive, non-cyclical demand. The 10-year horizon fits a durable oligopoly with a long specialty runway but no pricing power.

Value drivers

Revenue growth (Y1)10.0%
Terminal growth3.5%
Forecast horizon10y
Target operating margin1.8%
Years to target margin5
Sales-to-capital6.00
Beta0.85
Failure probability1.0%
Cost of capital (WACC)8.5%
Terminal WACC9.2%

Valuation bridge

PV of explicit FCFF15.35B
PV of terminal value71.95B
Equity value82.57B
÷ shares → per share$708.23

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 452.08B 10.0% 1.7% 6.21B 6.85B -639.37M -589.03M
2 494.02B 9.3% 1.7% 6.92B 6.99B -72.59M -61.60M
3 536.29B 8.6% 1.7% 7.65B 7.04B 608.02M 475.41M
4 578.30B 7.8% 1.8% 8.41B 7.00B 1.40B 1.01B
5 619.42B 7.1% 1.8% 9.17B 6.85B 2.31B 1.54B
6 659.00B 6.4% 1.8% 9.75B 6.60B 3.16B 1.93B
7 696.34B 5.7% 1.8% 10.31B 6.22B 4.08B 2.30B
8 730.77B 4.9% 1.8% 10.82B 5.74B 5.08B 2.63B
9 761.63B 4.2% 1.8% 11.27B 5.14B 6.13B 2.93B
10 788.28B 3.5% 1.8% 11.67B 4.44B 7.22B 3.18B

Key risks

  • GLP-1 pricing cuts or a shift to direct-to-consumer channels that remove distributor volume
  • Drug pricing reform (IRA negotiation, PBM/340B changes) compressing distribution economics
  • Loss or repricing of a major customer contract, or residual opioid litigation

Catalysts

  • Medical-Surgical spin-off simplifying the story and unlocking value
  • Continued oncology/specialty platform expansion and RxTS growth driving margin mix

History

DatePriceIntrinsicMoSRating
2026-11-05$1,069.44 $708.23 -33.8% BUY
2026-09-16$899.56 $631.23 -29.8% STRONG BUY
2026-07-28$850.06 $707.32 -16.8% STRONG BUY
2026-06-23$763.91 $737.76 -3.4% STRONG BUY